Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
NCT02358863
Terminated
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2018
Locations: Georgetown University, Washington, District of Columbia
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT01031446
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving cisplatin and paclitaxel together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2018
Locations: Erlanger Cancer Center at Erlanger Hospital - Baroness, Chattanooga, Tennessee +3 locations
Conditions: Breast Cancer
Register for Updates
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
NCT01445392
Terminated
Background: Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin. However, the benefits of this treatment are limited, and in most treated patients the disease continues to worsen. SS1(dsFV)PE38 is a genetically engineered drug. It contains an antibody that binds to a certain protein on mesothelioma cells and a toxin (type of poison) made from a product of a bacterium called Pseudomonas aeruginosa. It is hoped that the antibody will attach to the cancer cell... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/02/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Mesothelioma
Register for Updates
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
NCT01443078
Completed
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer. It is routine to give chemotherapy prior to surgery in patients with this type of lung cancer, to help keep it from coming back. It is also routine to perform a special type of scan called a PET scan. This PET scan measures how active a cancer is by use of a special tracer made... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2018
Locations: Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: Lung Cancer
Register for Updates
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
NCT00678132
Completed
Background: * AZD2281 is an experimental drug in a class of agents called PARP inhibitors. PARP is a protein that is involved in repairing DNA damage; PARP inhibitors interfere with that process. * Cisplatin and gemcitabine are approved by the United States Food and Drug Administration to treat certain cancers. Objectives: * To determine the optimum doses of AZD2281, cisplatin and gemcitabine in combination that can safely be given to patients with solid tumor cancers. * To evaluate the respo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Neoplasms
Register for Updates
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
NCT00045162
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who hav... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/03/2018
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +407 locations
Conditions: Lung Cancer
Register for Updates
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT01026467
Completed
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment regimen
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2018
Locations: Syracuse VA Medical Center, Syracuse, New York +1 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
NCT01732640
Terminated
Trial Objectives: The objective is to investigate the efficacy and safety of afatinib with induction chemotherapy in primary unresected patients with locally advanced, HPV-negative, stage III or IVa/b HNSCC including oral cavity, oropharynx, hypopharynx, or larynx. Primary Objective Phase I The primary objective of the phase I portion of the trial is to determine the maximum tolerated dose (MTD) or the recommended phase II dose of daily oral afatinib that is safe in combination with carboplati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2018
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
NCT00832637
Terminated
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC) patients with platelet counts 100,000/µL. The purpose of this study is to determine the tumor control rate following treatment with GEM-OX combined with Tarceva in patients with HCC. Tumor control rate is defined as the percentage of patients achieving a complete response, partial response, or stable disease at 24 w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2018
Locations: California Pacific Medical Center, San Francisco, California +1 locations
Conditions: Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
Register for Updates
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
NCT01009346
Terminated
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN). Secondary Objectives 1.To assess the toxicity of RAD001 in combination with weekly cetuximab and cisplatin on days 1 and 8 of each 28 day cycle in patients with recurrent or metastatic SCCHN,
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2018
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Head and Neck Cancer
Register for Updates
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
NCT00268450
Terminated
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blo... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2018
Locations: Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina +3 locations
Conditions: Bladder Cancer
Register for Updates
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
NCT00878449
Completed
This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2018
Locations: Site Reference ID/Investigator# 13323, Chicago, Illinois +6 locations
Conditions: Solid Tumors
Register for Updates